Facebook
Twitter
LinkedIn
ForwardMiami Cancer Institute Multispecialty Grand Rounds – Head and Neck Cancer 2020: Respecting the Old, Welcoming the New
Dr. Robert I. Haddad’s research has focused on the use of biologic agents and combined modality sequential and concurrent chemoradiotherapy in head and neck cancer. During this lecture he will discuss immune biomarker and genomic testing in head and neck cancer. Dr. Haddad will also address the survivorship of head and neck cancer.
Locations
| Live- MCI – Tumor Board Room - 3N110 |
| Webcast |
Target Audience
Oncologists, Radiation Oncologists, Hematology Oncologists, Radiation Therapists, General Surgeons, General Practitioners, Obstetricians and Gynecologists, Nurses, Social Workers, Patient Navigators and all other interested healthcare professionals.
Learning Objectives
- Implement sequential and concurrent chemoradiotherapy in head and neck cancer.
- Assess and identify the role of immunotherapy in head and neck cancer.
- Identify HPV and oropharynx cancer.
Robert Haddad M.D.
Division Chief, Head and Neck Oncology Program
Institute Physician
Dana Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Robert Haddad, M.D., indicated that he has received grant/research support from Merck, BMS, Genetech, Pfizer, Astra Zeneca and GSK. He has also served as a consultant with Merck, BMS, Genetech, Pfizer, Astra Zeneca, GSK, Celgene and Eisai. He will not include off-label or unapproved product usage in his presentation(s) or discussion(s).
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have relevant financial relationships to disclose.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1 credit hour, CE Broker Course #20-680158, by the Florida Boards of Medicine and Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 1 credit hour for Nursing, Nurse Practitioners, and Clinical Chaplains. Baptist Health South Florida CE Broker Provider #50-182.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General certificate of attendance
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Nursing
NOTE: Due to limited space, this conference is open to Baptist Health affiliated Medical Staff and Clinical Employees.
Required Hardware/Software
Technical Support: If you are experiencing technical difficulties or have received an error message, please send an email to CME@BaptistHealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.